Aarti Drugs Limited (IN:AARTIDRUGS)
:AARTIDRUGS
Want to see IN:AARTIDRUGS full AI Analyst Report?
AARTIDRUGS Stock Chart & Stats
₹404.80
-₹2.25(-0.50%)
At close: 4:00 PM EST
₹404.80
-₹2.25(-0.50%)
Day’s Range― - ―
52-Week Range₹318.60 - ₹574.95
Previous CloseN/A
Volume68.36K
Average Volume (3M)11.99K
Market Cap
₹34.23B
Enterprise Value₹40.08B
Total Cash (Recent Filing)₹245.40M
Total Debt (Recent Filing)₹5.73B
Price to Earnings (P/E)23.2
Beta0.98
Next Earnings
May 11, 2026Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)21.80
Shares Outstanding91,270,000
10 Day Avg. Volume14,342
30 Day Avg. Volume11,994
Financial Highlights & Ratios
PEG Ratio-16.53
Price to Book (P/B)2.30
Price to Sales (P/S)1.32
P/FCF Ratio46.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹480.00Price Target Upside18.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)24.7
Revenue Forecast (FY)₹29.50B
Bulls Say, Bears Say
Bulls Say
Manageable LeverageA reasonable debt-to-equity ratio and moderate balance-sheet stability reduce refinancing and liquidity risk over the medium term. That durable financial footing supports continued capex for capacity, compliance investments, or selective M&A without materially stressing cash flows or solvency.
Stable Profitability MarginsConsistent gross and net margins indicate the company can sustain profitability despite input cost swings. Durable margin levels support reinvestment in manufacturing, quality controls and margin-accretive specialty products, underpinning steady operating cash generation over multiple quarters.
Diversified API And Specialty Chemicals BusinessA diversified product mix across APIs, intermediates and specialty chemicals with domestic and export customers spreads demand risk and leverages regulatory-driven, long-term pharma and specialty-chemical markets. This structural exposure supports durable revenue channels and pricing power in niche chemistries.
Bears Say
Recent Revenue DeclineA recent drop in revenue signals weakening top-line momentum that can erode scale benefits and margin resilience. If structural (customer loss, pricing pressure or mix shifts), sustained revenue decline can reduce free cash flow and limit funding for capacity, R&D, or compliance investments.
Weak Free Cash Flow TrendsDeclining free cash flow growth and volatile operating cash flow constrain the company’s ability to self-fund capex, reduce debt, or return capital. Over months, weaker FCF raises dependence on external financing and limits strategic flexibility in pricing, capacity expansion, or margin-improvement programs.
Volatile Operating Margins (EBIT/EBITDA)Fluctuating EBIT/EBITDA margins increase earnings uncertainty and complicate long-term planning. Margin volatility may reflect variability in raw material costs, product mix or contract terms; persistent swings weaken forecasting accuracy and may pressure investor confidence and reinvestment capacity.
Aarti Drugs Limited News
AARTIDRUGS FAQ
What was Aarti Drugs Limited’s price range in the past 12 months?
Aarti Drugs Limited lowest stock price was ₹318.60 and its highest was ₹574.95 in the past 12 months.
What is Aarti Drugs Limited’s market cap?
Aarti Drugs Limited’s market cap is ₹34.23B.
When is Aarti Drugs Limited’s upcoming earnings report date?
Aarti Drugs Limited’s upcoming earnings report date is May 11, 2026 which is in 7 days.
How were Aarti Drugs Limited’s earnings last quarter?
Aarti Drugs Limited released its earnings results on Feb 03, 2026. The company reported ₹4.4 earnings per share for the quarter, missing the consensus estimate of ₹4.9 by -₹0.5.
Is Aarti Drugs Limited overvalued?
According to Wall Street analysts Aarti Drugs Limited’s price is currently Undervalued.
Does Aarti Drugs Limited pay dividends?
Aarti Drugs Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Aarti Drugs Limited dividends here
What is Aarti Drugs Limited’s EPS estimate?
Aarti Drugs Limited’s EPS estimate is 5.
How many shares outstanding does Aarti Drugs Limited have?
Aarti Drugs Limited has 91,270,000 shares outstanding.
What happened to Aarti Drugs Limited’s price movement after its last earnings report?
Aarti Drugs Limited reported an EPS of ₹4.4 in its last earnings report, missing expectations of ₹4.9. Following the earnings report the stock price went up 2.152%.
Which hedge fund is a major shareholder of Aarti Drugs Limited?
Currently, no hedge funds are holding shares in IN:AARTIDRUGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
AARTIDRUGS Stock 12 Month Forecast
Average Price Target
₹480.00
▲(18.58% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―